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Abstract
Merkel cell carcinoma (MCC) is an aggressive skin tumor with neuroendocrine differentiation, mainly affecting elderly 
population or immunocompromised individuals. As methylation of the human telomerase reverse transcriptase (mhTERT) 
has been shown to be a prognostic factor in different tumors, we investigated its role in MCC, in particular in intron 4–5 
where rs10069690 has been mapped and recognized as a cancer susceptibility locus. DNA methylation analysis of hTERT 
gene was assessed retrospectively in a cohort of 69 MCC patients from the University of Bologna, University of Turin 
and University of Insubria. Overall mortality was evaluated with Kaplan-Meier curves and multivariable Royston-Parmar 
models. High levels of mhTERT (mhTERThigh) (HR = 2.500, p = 0.015) and p63 (HR = 2.659, p = 0.016) were the only two 
clinico-pathological features significantly associated with a higher overall mortality at the multivariate analysis. We did not 
find different levels of mhTERT between MCPyV (+) and (−) cases (21 vs 14, p = 0.554); furthermore, mhTERThigh was 
strongly associated with older age (80.5 vs 72 years, p = 0.026), no angioinvasion (40.7% vs 71.0%, p = 0.015), lower Ki67 
(50 vs 70%, p = 0.005), and PD-L1 expressions in both tumor (0 vs 3%, p = 0.021) and immune cells (0 vs 10%, p = 0.002). 
mhTERT is a frequently involved epigenetic mechanism and a relevant prognostic factor in MCC. In addition, it belongs to 
the shared oncogenic pathways of MCC (MCPyV and UV-radiations) and it could be crucial, together with other epigenetic 
and genetic mechanisms as gene amplification, in determining the final levels of hTERT mRNA and telomerase activity in 
these patients.
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Introduction
Merkel cell carcinoma (MCC) is an aggressive neuroen-
docrine tumor, predominantly affecting elderly population 
or immunocompromised individuals [1, 2]. Although MCC 
is rare, its annual incidence has significantly increased in 
the last decades, probably due to population aging and the 
increase of risk factors as chronic sun damage and immu-
nosuppressive therapies [3, 4]. Despite aggressive therapeu-
tic strategies, MCC has a 5-year overall mortality of about 
33%, more than twice than that of cutaneous melanoma 
[4]. Therefore, deep insight into its genetic background 
could be crucial to improve targeted therapeutic strategies 
and outcomes of MCC patients. In the last years, several 
authors investigated the most commonly altered genes and 
genetic pathways (TP53, RB1, PIK3CA, KIT, PDGFRA, 
PDCD1, chromosomal abnormalities, miRNAs, and many 
others) in MCC [5–12]. They found that a number of onco-
genes and tumor-suppressor genes, even if not mutated, are 
abnormally up- or down-regulated in MCC, through dif-
ferent epigenetic mechanisms [5–12]. Telomerase (TERT), 
an RNA-dependent DNA polymerase, represents one of 
the crucial steps in the malignant transformation of sev- 
eral tumors, stabilizing the telomere length and immor- 
talizing cancer cells [9, 13–15]. The functional catalytic 
subunit of TERT (human telomerase reverse transcriptase-
hTERT), is up-regulated through multiple genetic and epi-
genetic mechanisms, including hTERT promoter mutations, 
amplifications, promoter methylation, alternative splicing, 
and many others [9, 13–15]. Although hTERT has a well-
established pathogenetic and prognostic role in several 
tumors, it has been poorly investigated in MCC and little is 
known about its function in this neoplasia [9, 16, 17]. Xie 
H. et al. showed that there is a widespread hTERT mRNA 
expression in MCC and that higher hTERT mRNA levels 
are associated with a significantly shorter overall survival 
[9]. Nevertheless, they only investigated hTERT promoter 
mutations and amplifications and, as clarified by the same 
authors, the complex genetic and epigenetic regulation sys-
tem of hTERT expression in MCC is still largely unknown 
[9]. Genome-wide association studies (GWAS) have 
recently mapped risk alleles for at least 10 cancer types in a 
region of chromosome 5 (5p15.33), harboring hTERT gene 
[18]. Allele-specific effects on DNA methylation were seen 
in this region identifying the single-nucleotide polymor-
phism (SNP) biomarker rs10069690 as a possible effector 
on the methylation and subsequently on gene expression 
[18, 19]. In this work, we decided to evaluate epigenetic 
modifications with regard to DNA methylation in this pre-
cise region not located on the promoter but within the intron 
(mhTERT) [18, 19]. We previously characterized DNA 
methylation alterations in this locus in a large cohort of oral 
squamous cell carcinoma, identifying the most correlated 
CpG located at Chr5:1279643-1279644, with an area under 
the curve (AUC) of 0.92 [18, 19]. Since mhTERT could be a 
relevant epigenetic mechanism in hTERT expression and an 
independent prognostic factor in several tumors, we investi-
gated whether mhTERT is associated with overall mortality 
and with the most relevant clinical-pathological features in 
a series of MCC patients [9, 13–32].
Materials and Methods
Ethics Statement
All clinical investigations were conducted according to the 
principles of the Declaration of Helsinki. The study was 
approved by the Institutional Review Board and the local eth-
ics committee (study number CE18083, DIBINEM-UNIBO- 
rif.CE AVEC number 377/2018/OSS/AUSLBO). All infor-
mation regarding the human material used in this study was 
managed using anonymous numerical codes.
Patients and Specimens
This is a multicentric study enrolling 69 subjects from three 
different Italian Universities: University of Turin (31 cases), 
University of Bologna (31 cases), and University of Insubria 
(7 cases). This cohort has been previously published by our 
group in a study on mPDCD1, and the follow-up has been 
updated [8]. All tumors were re-staged according to the  8th 
edition of the AJCC Cancer Staging Manual [4]. Tissues were 
fixed in 10% formalin, embedded in paraffin, and stained with 
hematoxylin and eosin (H&E). Slides from each case were 
reviewed by five pathologists (S.A., S.U., S.L.R., F.M., C.R.) 
to confirm the diagnosis and restage the tumors, to assess 
pathological parameters, and to choose one representative par-
affin block for additional analyses. We evaluated the immune 
cells (ICs) rather than the tumor-infiltrating lymphocytes 
(TILs), as previously reported [33–35].
Immunohistochemistry
Immunohistochemistry (IHC) was performed on archival, 
formalin-fixed, paraffin-embedded tissues, using the follow-
ing antibodies: PD-L1 (clone 123 C3SP142, Ventana-Diapath, 
dilution 1:50), CD3 (clone 2GV6, Ventana-Diapath, dilu-
tion RTU), Cytokeratin 20 (clone SP33, Ventana, dilution 
RTU), Chromogranin (clone LK2H10, Ventana, dilution 
RTU), TTF-1 (clone 847G3/1, Ventana, dilution RTU), and 
Ki67 (clone MIB-1, Dako, dilution 1:100). PD-L1 positivity 
was assessed on ICs and tumor cells (TCs), as previously 
described by Lipson et al. [34].
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DNA Mutation Analysis of hTERT Promoter
DNA Purification
DNA from macrodissected tumor tissue was digested at 56 °C 
for 3 h to over-night using the Quick Extract™ FFPE DNA 
extraction kit (Epicentre, Madison, WI, USA). A denaturation 
step at 95 °C for 5 min, followed by centrifugation at 10,000×g 
at 4 °C for 5 min, was adopted to pellet the undigested tissue 
and solidify the paraffin afloat. DNA was collected from the 
interphase and stored at 4 °C. hTERT promoter mutation analy-
sis was performed by next-generation sequencing (NGS) using 
a two-step PCR protocol, as previously described [36]. The 
region of interest spanned the two most common mutations 
including C228T (c.-124C>T) and C250T (c.-146C>T) (Chr5: 
1295035-1295199 keeping hg38 as a reference genome ver-
sion). Each NGS experiment was designed to allocate at least 
2 k reads/region aimed to have a depth of coverage of at least 
2000×. Reads were mapped in a Galaxy Project environment to 
the hg38 human reference genome with Bowtie2, GATK local 
realignment, HaplotypeCaller, and Picard MarkDuplicates 
[37]. Mutations were visualized using BAM files loaded onto 
the Integrative Genomic Viewer (IGV); only mutations with a 
variant allele frequency (VAF) threshold > 5% were reported.
Quantitative DNA Methylation Analysis of hTERT 
(mhTERT)
Bisulfite DNA Treatment
Bisulfite treatment of genomic DNA was carried out with the 
EZDNA Methylation-Lightning™ Kit (Zymo Research, cod. 
D5031) according to the manufacturer’s protocol.
Bisulfite Next‑Generation Sequencing analysis
Quantitative DNA methylation analysis was performed by 
bisulfite-next-generation sequencing as previously described 
[19]. The library was prepared in two steps: a first multi-
plex PCR amplification for target enrichment and a second 
round of amplification for barcoding which was performed 
using the Nextera™ index kit. MethPrimer (http:// www. 
uroge ne. org/ cgi- in/ methp rimer/ methp rimer. cgi) was applied 
to identify CpGs and the best primers of choice for hTERT 
[38]. Three regions of interest were evaluated: the promoter 
region A as indicated previously by Svahn et al. with the fol-
lowing mapping coordinates: Chr5: 1295506-1295709, the 
promoter region B with mapping coordinates Chr5: 1295027-
1295220, and an additional region previously described by 
Morandi et al. spanning from Chr5: 1.279.604 to 1.279.759 
(intron-4–5) (keeping hg38 as a reference) (mhTERT) [19, 
39]. Six different CpGs are located in this region: 1279732, 
1279723, 1279714, 1279660, 1279643, 1279631. Amplicons 
were purified using MagSi-NGSPREP beads (Magnamedics, 
Geleen, The Netherlands), quantified with Fluorometer 
Quantus™ (Promega, Madison, WI, USA), and then pooled 
and loaded on Illumina MiSEQ (Illumina, San Diego, CA, 
USA) according to the manufacturer’s protocol.
Bisulfite Sequencing Data Analysis
Each NGS experiment was designed to allocate at least 
2 k reads/region, in order to have a depth of coverage of 
about 2000× to allow a good estimate of DNA methylation 
level. The methylation ratio of each CpG was calculated in 
a Galaxy Project environment (Europe) using BWA-meth 
for mapping and generating the bam file followed by the 
MethylDackel tool [37]. In parallel, DNA methylation level 
and quality control of various FASTQ files were evaluated 
using the web-tool EPIC-TABSAT [40].
Statistical Analysis
hTERT methylation levels (mhTERT) have been dichot-
omized according to the obtained median value (0.97) 
chosen as threshold (Fig. 1). In brief, the tumor was strati-
fied in mhTERThigh if the methylation levels of the CpGs 
mapped on Chr5:1279643-1279642, Chr5:1279660-
1279659, Chr5:1279714-1279713, Chr5:1279723-
1279722 were all above the cut-off threshold (0.97); on 
the contrary, mhTERTlow was assigned if even just one was 
below the threshold (range of methylation = 0.33–1.000). 
Continuous variables were dichotomized according to 
sensible cutoffs in order to be used for survival analysis. 
Patients have been aggregated in two groups for age ≥ or 
< 75 years (corresponding to the population mean age), 
tumor size ≥ 2 cm, mitosis ≥ 10/high-power field (HPF), 
Ki67 ≥ 50%, tumor thickness ≥ 10 mm. Because Ki67 
dichotomized according to cut-off of < 55%/≥ 55% was 
not an independent predictor of survival at the multivari-
ate analysis as recently reported by our group, we adopted 
the cut-off of < 50%/≥ 50% according to our previous 
data [41–43] Stage was dichotomized into two classes, 
I-II (low stages) and III-IV (high stages). Patients’ char-
acteristics were compared across mhTERT status using 
chi-square or Mann-Whitney test. Overall survival (OS) 
was evaluated by means of incidence rate ratios and sur-
vival analysis using Kaplan-Meier curves and multivari-
able Royston-Parmar (RP) models. These models have 
the advantage, over the more traditional Cox regression 
approach, to allow a greater flexibility in the specification 
of the baseline log cumulative survival function, which 
provides a better fit to the data and, as a consequence, 
an improvement of model accuracy [44, 45]. RP models 
use restricted cubic splines with an appropriate number 
of knots to fit even complex mathematical functions that 
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best represent the survival function inherent to the data 
[44, 45]. We selected the most appropriate functional 
form among proportional hazards models, proportional 
odds models, and probit models with 1 to 5 evenly spaced 
knots, based on the lowest values of the Akaike informa-
tion criterion (AIC) and Bayesian information criterion 
(BIC) statistics, which denote the better fit to the data. 
After identifying the survival function, the multivariable 
fractional polynomial (MFP) procedure was used to select 
the variables influencing OS from a set of initial candi-
date predictors. MFP automatically performs backward 
selection by removing the weakly significant predictors 
and identifies the most appropriate functional form of 
the relationships between the outcome and the continu-
ous covariates, thus improving model accuracy [46]. The 
initial model was estimated using mhTERT status as main 
exposure and age, gender, tumor size, tumor thickness, 
angioinvasion, p63, MCPyV, clinical stage III-IV, PD-L1 
in TCs ≥ 5%, and infiltrative growth as covariates and 
obtaining robust standard errors for patients clustering 
into centers. In the backward selection process of MFP, 
mhTERT was imposed to be retained in the model, as 
well as covariates with p < 0.100. This confidence level 
was chosen in order to keep in the final model the vari-
ables that may not reach a p value lower than the standard 
0.05 confidence level only because of the small sample 
size, although showing a remarkable effect on OS. Lastly, 
the model-adjusted survival curves of mhTERT and the 
retained clinical-pathological parameters were estimated. 
All analyses have been carried out using Stata v.15.1, 
specifically the stpm2 procedure was used to estimate 
RP models [47].
Fig. 1  The lollipop graph displays the percent methylation per CpG 
position for 10 randomly selected samples, 5 mhTERThigh cases, and 
5 mhTERTlow ones, respectively. The color of the circles represents 
the percent methylation as shown in the color legend on the right side 
of the plot. On the lower x-axis, the genomic positions of the CpGs 
are displayed, the upper x-axis shows the summarized average percent 
methylation for this CpG position




The clinico-pathological features of the cohort have already 
been described in a previous study [8]. In brief, the study 
cohort included a total of 69 patients, 38 (55.1%) males, and 
31 (44.9%) females, with a median age of 77 years. Accord-
ing to the  8th edition of the AJCC Cancer Staging Manual, 
localized disease (AJCC Clinical Stage I-II) was present in 
45 (65.2%) and advanced (AJCC Clinical Stage III-IV) in 24 
(34.8%) patients, with only two (2.9%) patients displaying 
distant metastases (AJCC Clinical Stage IV) [4]. Pathological 
stage was available only for 28 patients (41%) because only 
after 2010, the SLNB has been recommended in all patients 
with localized disease [4, 48]. Patients were followed up for 
a maximum time of 192 months. At the end of follow-up, 39 
(56.5%) patients died, 35 (50.7%) due to MCC (DOD) and 
4 (5.8%) of other causes (DOC). The median follow-up time 
was 24 months (range 2–150) for DOD, 17 months (range 
14–60) for DOC, and 46.5 months (range 6–192) for patients 
still alive at follow-up. At the end of follow-up, 9 patients 
(13.0%) were alive with disease progression (AWD) and 21 
ones (30.4%) had no evidence of disease (NED).
hTERT Promoter Mutation Analysis
Only three cases showed the hTERT promoter mutation 
C250T (c.-146C>T) with a variant allele frequency below 
7% for all.
DNA Methylation of Intron 4–5 (mhTERT) 
and Correlation with Clinico‑pathological Features
The study population was composed by 30 (43.5%) patients 
with mhTERThigh and 39 (56.5%) patients with mhTERTlow, 
whose clinical-pathological features are summarized in 
Table 1. Patients with mhTERThigh differed significantly for 
an older median age (80.5 vs 72 years, p = 0.026), but a lower 
angioinvasion (40.7% vs 71.0%, p = 0.015), Ki67 expression 
Table 1  Clinical-pathological 
data of the study population, 
divided in mhTERTlow and 
mhTERThigh groups
n number of patients for which clinical-pathological features were present and/or evaluated, ICs immune 
cells, TCs tumor cells, HPF high-power filed, p63 protein p63, IHC immunohistochemistry, MCPyV Merkel 
cell polyomavirus, Ki67 proliferation index Ki67/MIB1, PD-L1 programmed death-ligand 1, mhTERTlow 
low level of mhTERT, mhTERThigh high level of mhTERT
a Mann-Whitney test
n Study population, 






Study population 69 69(100.0) 39(56.5) 30(43.5)
Age, median(range) 69 77(41–95) 72(41–95) 80.5(59–89) − 2.22; 0.026a
Age ≥ 75 years 69 41(59.4) 17(43.6) 24(80.0) 9.32; 0.002
Males 69 38(55.1) 22(56.4) 16(53.3) 0.06; 0.799
Size, median(range) 65 2.5(0.3–8.5) 2.5(0.3–6.5) 2.4(0.6–8.5) 0.440; 0.660a
Size ≥ 2 cm 69 38(55.1) 23(59.0) 15(50.0) 0.55; 0.458
Clinical stage III-IV 69 24(34.8) 13(33.3) 11(36.7) 0.08; 0.773
Tumor thickness, mm 65 12(1–45) 12.5(1–22) 10(1–45) 1.13; 0.257a
Tumor thickness ≥ 10 mm 65 37(56.9) 24(63.2) 13(48.1) 1.45; 0.228
Angioinvasion 65 38(58.5) 27(71.0) 11(40.7) 5.97; 0.015
Mitosis ≥ 10/HPF 69 40(58.0) 21(53.8) 19(63.3) 0.63; 0.429
p63-IHC 69 13(18.8) 7(17.9) 6(20.0) 0.05; 0.829
MCPyV 69 35(50.7) 21(53.8) 14(46.7) 0.35; 0.554
Ki67, median(range) 69 60(10–100) 70(30–100) 50(10–95) 2.83; 0.005a
Ki67 ≥ 50% 69 42(60.9) 28(71.8) 14(46.7) 4.50; 0.034
ICs 65 34(52.3) 23(60.5) 11(40.7) 2.48; 0.116
Infiltrative growth 65 22(33.8) 16(42.1) 6(22.2) 2.79; 0.095
PD-L1 ICs 65 3(0–70) 10(0–70) 0(0–50) 3.11; 0.002a
PD-L1 TCs 69 1(0–30) 3(0–30) 0(0–20) 2.31; 0.021a
Site 69 1.36; 0.508
Head and neck 26(37.7) 14(35.9) 12(40.0)
Extremities 28(40.6) 18(46.2) 10(33.3)
Trunk 15(21.7) 7(17.9) 8(26.7)
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(50 vs 70%, p = 0.005) and PD-L1 expressions in both TCs 
(0 vs 3%, p = 0.021 as continuous variable; 7 vs 17, p = 0.080 
with cut-off of 5%), and ICs (0 vs 10%, p = 0.002 as continu-
ous variable; 7 vs 23, p = 0.006 with cut-off of 5%). There was 
no difference in the distribution of mhTERT levels between 
MCPyV (+) and (−) cases (21 vs 14, p = 0.554). Among 
the 39 patients with a fatal outcome, 22 (56.4%) were in the 
mhTERThigh group and 17 (43.6%) in the mhTERTlow one. 
The mortality incidence ratio of mhTERThigh/mhTERTlow was 
1.648 (95% CI: 0.836–3.305), suggesting higher, although 
not statistically significant, mortality in mhTERThigh group. 
The Kaplan-Meier survival analysis confirmed this result 
(log-rank test: t = 2.76, p = 0.097; Fig. 2) and showed that 
the curves diverge about 12 months after the surgery. Other 
clinical-pathological features associated to a higher mortality 
risk in the bivariate analysis were clinical stage III-IV (log-
rank test: t = 4.16, p = 0.041), p63 (log-rank test: t = 13.12, 
p < 0.001), and absence of MCPyV (log-rank test: t = 11.62, 
p = 0.001). In the final multivariable RP model, mhTERThigh 
was confirmed as associated to a lower OS (HR = 2.500, 
p = 0.015) also after adjusting for p63 (HR = 2.659, p = 0.016) 
absence of MCPyV (HR = 0.478, p = 0.056) and angioinva-
sion (HR = 2.168, p = 0.060), while all the other covariates 
were removed because they did not show a remarkable influ-
ence on OS (p > 0.100) (Table 2 and Fig. 3).
hTERT Promoter Methylation
DNA promoter methylation for regions A and B as previ-
ously described was available in only 13 cases [39]. This 
was due for overfixation problems, bisulfite treatment and 
for the amplicon length, which was higher than for intron 
4–5 locus. Region A, spanning from Chr5: 1295506 to 
1295709, revealed full methylation in all cases except for 
two, both showing mhTERTlow. Region B spanning from 
Chr5: 1295027 to 1295220 was found to be hypomethylated 
(ranged from 50 to 0% methylation) in all cases. Due to lack 
of data for most of cases, additional statistical analysis was 
not performed.
Discussion
Three main findings emerge from this study on mhTERT 
in MCC:
1. mhTERT is an epigenetic mechanism frequently activated 
in MCC, in particular in a locus mapped on intron 4–5 
around the SNP variant rs10069690, which was previ-
ously described as correlated with several cancer types by 
genome-wide association studies [18];
Fig. 2  Kaplan-Meier survival 
curve shows a higher mortality 
in mhTERThigh group (log-rank 
test: t = 2.76, p = 0.097), with 
the curves diverging about 
12 months after the surgery
Table 2  Results of the multivariable Royston-Parmar model (n = 65)
CI confidence interval, HR hazard ratio, mhTERThigh high level of 
mhTERT, p63 protein p63, IHC immunohistochemistry, MCPyV Mer-
kel cell polyomavirus
HR 95% CI p value
mhTERThigh 2.500 1.193–5.236 0.015
Angioinvasion 2.168 0.966–4.863 0.060
p63-IHC 2.659 1.203–5.877 0.016
MCPyV 0.478 0.224–1.020 0.056
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2. mhTERT is an epigenetic mechanism involved in both 
MCPyV (+) and (−) MCC, but had a different distribution 
when compared with specific clinical-pathological features 
(age, angioinvasion, Ki67, and PD-L1 expression);
3. mhTERThigh was related to a higher mortality risk when 
adjusted for the main clinico-pathological features.
hTERT is the functional subunit of the enzyme TERT and 
it is crucial to erase senescence and immortalize tumor cells 
[13–15]. Numerous epigenetic mechanisms are involved in 
hTERT expression, and among these, one of the most studied 
is its promoter methylation [13–15]. For the majority of the 
genes, hypo-methylation of the promoter is fundamental to 
permit an active transcription [13–15]. Nevertheless, several 
studies showed that hypermethylation of hTERT was para-
doxically associated with higher hTERT mRNA levels and 
telomerase activity depending on the region of interest inves-
tigated [13–32]. Although several mechanisms cooperate in 
determining the final telomerase activity, promoter methylation 
proved to be one of the most relevant ones, singly affecting 
survival, recurrence, and progression in pediatric brain tumors, 
meningiomas, head and neck squamous cell carcinoma, leu-
kemias, prostatic adenocarcinoma, and several other tumors 
[17–32]. In our series, we investigated not only the promoter 
but also a region of intron 4–5, where the SNP rs10069690 has 
been mapped (mhTERT) [18, 19]. This locus was previously 
associated with estrogen- and progesterone receptor-negative 
breast cancer, glioma, prostate, testicular germ cell, pancreas, 
and urinary bladder [18, 19]. It is becoming clear that regions 
with variable methylation tend to be mapped also in the gene 
body, overlapping known regulatory elements enriched for 
disease-associated SNPs [18, 19, 49]. These results are prom-
ising from a therapeutic point of view, for the availability of 
therapies inducing demethylation and repression of hTERT 
expression, as just shown in carcinoma cell lines and other 
in vitro studies with the demethylating agent [50, 51]. This 
is the first study that investigated frequency, association with 
clinical-pathological features, and prognostic relevance of 
mhTERT within the gene body (intron 4–5) in MCC patients. 
Xie et al. showed that hTERT expression is widespread in 
Fig. 3  In the final multivariable RP model, mhTERThigh (p = 0.015) and 
p63 (p = 0.016) strongly influenced overall survival, whit borderline- 
significant associations for angioinvasion (p = 0.060) and absence of 
MCPyV (p = 0.056). Blue-dashed line: mhTERTlow or absence of exam-
ined parameter (p63, angioinvasion and MCPyV); red line: mhTERThigh 
or presence of examined parameter (p63, angioinvasion and MCPyV)
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MCC and higher hTERT mRNA levels are associated with a 
shorter OS [9]. Furthermore, the only two genetic mechanisms 
analyzed by the authors were promoter mutation (1/6 cell lines 
and 4/35 MCC cases) and gene amplification (1/6 cell lines 
and 11/14 MCC cases) [9]. As clarified by the same authors, 
these two genetic alterations could only partially explain the 
diffuse hTERT mRNA expression (6/6 cell lines and 41/43) 
and telomerase activity (6/6 cell lines and 11/11 MCC cases) 
[9]. Unfortunately, for tissue overfixation of several enrolled 
cases, we were not able to obtain good quality RNA to moni-
tor hTERT gene expression level, so we could not correlate 
it with DNA methylation. In line with these findings, other 
studies showed that hTERT promoter mutation is infrequent 
in MCC and suggested that other epigenetic mechanisms are 
probably involved [16, 17]. Our series confirmed these data 
as only three cases showed the mutation C250T (c.-146C>T) 
with very low allele frequency below 7%. The first main 
finding coming out from our study is that mhTERThigh is an 
epigenetic mechanism frequently involved in MCC (30/69, 
43.5%). Although this result needs to be validated in larger 
case series, it suggests that mhTERT could be one important 
epigenetic mechanism involved in hTERT regulation, cooperat-
ing with other ones to justify the high levels of hTERT mRNA 
and telomerase activity found in these patients. The second 
main finding is the prognostic impact of mhTERThigh, as just 
observed in other tumors [17–32]. In the multivariable model, 
we found that only mhTERThigh and p63 affected OS, with mar-
ginal significance for angioinvasion and absence of MCPyV. 
In addition, Kaplan-Meier analyses showed that mhTERThigh 
displays its effect on survival since about 12 months after the 
surgery. This finding suggests that mhTERThigh could be a 
middle- and long-term response predictor, as shown for other 
pathological features [8]. In addition, we found that mhTER-
Thigh was a strong prognostic factor regardless its association 
with other unfavorable and favorable prognostic factors. Xie 
et al. found that, despite hTERT mRNA levels were associ-
ated with a shorter OS and they were strongly influenced by 
promoter mutation and gene amplification, these two genetic 
mechanisms did not affect the prognosis when singly evaluated 
[9]. This result is in line with what found by other authors in 
other tumors, where hTERT mRNA levels but not mhTERT 
promoter methylation affects the prognosis [30, 31]. A possible 
explanation, provided by the same authors and supported by us, 
is that mechanisms specifically regulating the levels of hTERT 
mRNA are differently involved in each tumor [9, 13–30]. This 
would explain why hTERT mRNA levels affect prognosis in 
almost all tumors but a singly evaluated mechanism could do it 
or not [9, 13–32]. Additionally, TERT promoter mutations have 
been shown to be spatially heterogeneous/sub-clonal in some 
tumors (follicular thyroid carcinoma, follicular thyroid tumors 
of uncertain malignant potential and meningiomas) and sev-
eral genes (MLH1, MGMT, CDKN2B) could exhibit spatially 
heterogeneous/sub-clonal methylation patterns in different 
tumors (glioblastoma, breast carcinoma) [52–58]. Although 
these aspects have never been investigated in MCC, it is not 
possible to exclude that mhTERT and promoter methylation 
could be spatially heterogeneous/sub-clonal in this tumor 
and, as result, our data could be affected by the tissue/block 
selection. Future studies adopting single-cell sequencing will 
help to clarify if mhTERT and promoter methylation are het-
erogeneous/sub-clonal in MCC and if there are small fraction 
of tumor cells (i.e., tumoral stem cells) which could acquire 
hTERT demethylation in one allele causing small changes in 
overall DNA methylation. It is largely accepted that MCPyV 
and UV-radiations identify two divergent pathogenetic path-
ways in MCC, with many differences in the genetic landscape 
[5–8]. MCPyV (−) MCCs have a high mutation burden, fre-
quent mutations in RB1, TP53, genes involved in chromatin 
remodeling (ASXL1, MLL2, and MLL3), and DNA damage 
[5–8]. By contrast, MCPyV (+) MCCs have a low mutation 
burden, reduced expression of H3K27me3, and no mutations 
in the previous listed genes [5–8]. Nevertheless, in both sub-
groups, there are involvement of common transcription fac-
tors (NFAT, P-CREB, and P-STAT3) and mutations in PI3K 
(HRAS, KRAS, PIK3CA, PTEN, and TSC1) and Notch path-
ways genes (Notch1 and Notch2), supporting the presence of 
shared oncogenic pathways in both MCPyV (+) and (−) MCCs 
[5]. We did not find different distribution of mhTERT levels 
between MCPyV (+) and (−) cases, suggesting that mhTERT 
belong to the shared oncogenic pathways. This hypothesis is 
supported by the absence of correlation between mhTERT 
and site (Table 1), with this latter known to be associated 
with the pathogenetic pathway [trunk: MCPyV (+); head-
and-neck and extremities: MCPyV (−)] [3]. According to our 
findings, Chteinberg E et al. found that DNA methylation age 
(DNAmAge) is not associated with MCPyV in MCC, as previ-
ously described for other viral infections as HPV or EBV [59]. 
In addition, Xie et al. found that absence of virus was associ-
ated with promoter mutation (in line with the higher mutation 
burden of MCPyV (−) MCC) but none with gene amplification 
and hTERT mRNA levels, supporting that hTERT could be 
involved in both pathogenic pathways [9].
Conclusion
In conclusion, our study showed that mhTERT in intron 4–5 in 
proximity of the SNP rs10069690 strongly affects the prognosis 
of MCC patients, being involved in both MCPyV (+) and (−) 
tumors, cooperating with other epigenetic and genetic mecha-
nisms as gene amplification in determining the final levels of 
hTERT mRNA and telomerase activity. Future studies with 
larger case series are needed to clarify the relationship between 
mhTERT, the other genetic and epigenetic mechanisms involved 
in the hTERT regulation, the pathogenesis (MCPyV and UV-
radiations), and prognosis.
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